The CEO of Biogen Idec confronts a set of tough choices regarding a promising drug for Multiple Sclerosis that's headed for early acceptance by the FDA. The first in a series, focuses on operational choices activated by the drive for early approval. Sparks discussion about a leader's economic, legal, and ethical duties to multiple constituencies, and how a leader can guide a business to perform efficiently, fulfilling those duties, in a situation that is complex.
Decisions facing the firm include how to secure insurance company compensation, and how to support credible research on the drug's effectiveness and safety, the way to increase production capacity to meet anticipated demand. All of these challenges appear against the backdrop of the accelerated approval process, uncertainty about what the FDA will ultimately determine, and whether the firm should really pursue early acceptance.
PUBLICATION DATE: November 14, 2007 PRODUCT #: 412C08-HCB-CHI
This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE
Related Case Solutions & Analyses:
Utah Symphony and Utah Opera: Merger Proposal
General Managers Operational Challenge: Managing Through People
Apple Computer (C1): Reorganizing the Human Resource Function
Practical Guide to Settling Into a New Executive Position
MIT Mystery Hunt: The Answer is Secondary
Rethinking Cities: Chicago on the Move
CBM Pte Ltd – Industry’s ‘Silent Service’?
Learning Resources: A Hands-On Toy Company Deals with New Challenges and Opportunities
Green Rubber: The Revolution of the Rubber Recycling Business
How to Manage Through Worse-Before-Better
